Listed

Black Diamond Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2020

Filed with the SEC on May 12, 2020 and accepted by EDGAR at May 12, 2020, 07:34 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-01-01 to 2020-03-31$7.4mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-01-01 to 2020-03-31−$12.9mus-gaap:OperatingIncomeLoss
Net income3 months2020-01-01 to 2020-03-31−$12.1mus-gaap:NetIncomeLoss
Operating cash flow3 months2020-01-01 to 2020-03-31−$11.3mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2020-01-01 to 2020-03-31$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-03-31$357.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-03-31$362.1mus-gaap:AssetsCurrent
Total assetsAt period end2020-03-31$362.8mus-gaap:Assets
Current liabilitiesAt period end2020-03-31$7.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-03-31$7.5mus-gaap:Liabilities
Shareholders' equityAt period end2020-03-31$355.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001701541-20-000018. Last ingested by Listed: Nov 10, 2026, 16:37 ET. Listed shows no prices and gives no investment advice.